Literature DB >> 12187481

p53 Immunoreactivity, Ki-67 expression, and microcirculation patterns in melanoma of the iris, ciliary body, and choroid.

Itay Chowers1, Robert Folberg, Nelly Livni, Jacob Pe'er.   

Abstract

PURPOSE: The major role of p53 is to modulate cell proliferation, but recently, it has been found that p53 also modulates angiogenesis through several pathways. Because both cellular proliferation and microcirculation patterns are important prognostic markers in uveal melanoma, we tested the relationships between p53 expression, the expression of the cell proliferation marker Ki-67, and the presence of various microcirculation patterns in uveal melanoma.
METHODS: Immunostaining of p53 and Ki-67 using the bp53.12 and the MIB-1 antibodies, respectively, were preformed in 98 uveal melanomas (18 melanomas confined to the iris, 30 ciliary body melanomas, and 50 choroidal melanomas). Percent of p53 positive cells, and the mean MIB-1 positive cell count per high power field were calculated in each section by two observers. Microcirculation patterns were assessed in adjacent PAS stained sections.
RESULTS: p53 immunoreactivity was found in 14 of the 98 melanomas. High proliferative activity and epithelioid cell type were associated with p53 immunoreactivity. However, p53 immunoreactivity was not associated with any of the microcirculation patterns or with tumor location.
CONCLUSIONS: The findings suggest that alterations in p53 expression are associated with the expression of the cellular proliferation marker, Ki-67, but are not associated with the presence of microcirculation patterns.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187481     DOI: 10.1076/ceyr.24.2.105.8166

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  7 in total

1.  Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility.

Authors:  Shoujian Wang; Aneesh Neekhra; Daniel M Albert; Christine M Sorenson; Nader Sheibani
Journal:  Arch Ophthalmol       Date:  2012-03

2.  Association between gene expression profile, proliferation and metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; J William Harbour
Journal:  Curr Eye Res       Date:  2010-09       Impact factor: 2.424

3.  Immunohistochemical study of vascular endothelial growth factor (VEGF), tumor suppressor protein (p53) and intercellular adhesion molecule (ICAM-1) in the conjunctiva of diabetic patients.

Authors:  Lidia Kria; Taoufik Khalfaoui; Ghada Mkannez; Omar Beltaief; Raja Anane; Khalil Errais; Lilia Tounsi; Raja Zhioua; Sarra Ben Jilani; Amel Meddeb Ouertani
Journal:  J Mol Histol       Date:  2006-02-16       Impact factor: 2.611

4.  A comparative transcriptomic analysis of uveal melanoma and normal uveal melanocyte.

Authors:  Jianhong An; Haolei Wan; Xiangtian Zhou; Dan-Ning Hu; Ledan Wang; Lili Hao; Dongsheng Yan; Fanjun Shi; Zhonglou Zhou; Jiao Wang; Songnian Hu; Jun Yu; Jia Qu
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

Review 5.  Proteomics of uveal melanoma: a minireview.

Authors:  Søren K O Abildgaard; Henrik Vorum
Journal:  J Oncol       Date:  2013-09-03       Impact factor: 4.375

6.  Monosomy-3 Alters the Expression Profile of the Glucose Transporters GLUT1-3 in Uveal Melanoma.

Authors:  Tjorge Maaßen; Siranush Vardanyan; Anton Brosig; Hartmut Merz; Mahdy Ranjbar; Vinodh Kakkassery; Salvatore Grisanti; Aysegül Tura
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

7.  Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.

Authors:  Guillaume Carita; Estelle Frisch-Dit-Leitz; Ahmed Dahmani; Chloé Raymondie; Nathalie Cassoux; Sophie Piperno-Neumann; Fariba Némati; Cécile Laurent; Leanne De Koning; Ensar Halilovic; Sebastien Jeay; Andrew Wylie; Caroline Emery; Sergio Roman-Roman; Marie Schoumacher; Didier Decaudin
Journal:  Oncotarget       Date:  2016-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.